메뉴 건너뛰기




Volumn 13, Issue 4, 2007, Pages 497-499

Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THALIDOMIDE; THIOTEPA;

EID: 33947272722     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.01.069     Document Type: Letter
Times cited : (5)

References (10)
  • 1
    • 0142152420 scopus 로고    scopus 로고
    • Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of multiple myeloma
    • Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of multiple myeloma. Blood 102 (2003) 3447-3454
    • (2003) Blood , vol.102 , pp. 3447-3454
    • Maloney, D.G.1    Molina, A.J.2    Sahebi, F.3
  • 2
    • 21844479269 scopus 로고    scopus 로고
    • Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma
    • Kroger N. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma 46 (2005) 813-821
    • (2005) Leuk Lymphoma , vol.46 , pp. 813-821
    • Kroger, N.1
  • 3
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
    • (2003) N Engl J Med , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 4
    • 0037441760 scopus 로고    scopus 로고
    • Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    • Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
    • (2003) Blood , vol.101 , pp. 1530-1534
    • Hideshima, T.1    Mitsiades, C.2    Akiyama, M.3
  • 5
    • 2542599273 scopus 로고    scopus 로고
    • Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
    • Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101 (2004) 8120-8125
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 8120-8125
    • Sun, K.1    Welniak, L.A.2    Panoskaltsis-Mortari, A.3
  • 6
    • 30444458109 scopus 로고    scopus 로고
    • NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS1145
    • Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., and Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS1145. Blood 107 (2006) 827-834
    • (2006) Blood , vol.107 , pp. 827-834
    • Vodanovic-Jankovic, S.1    Hari, P.2    Jacobs, P.3    Komorowski, R.4    Drobyski, W.R.5
  • 7
    • 33646685024 scopus 로고    scopus 로고
    • Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status
    • Kroger N., Zabelina T., Ayuk F., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 34 (2006) 770-775
    • (2006) Exp Hematol , vol.34 , pp. 770-775
    • Kroger, N.1    Zabelina, T.2    Ayuk, F.3
  • 8
    • 33745747909 scopus 로고    scopus 로고
    • Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation
    • Bruno B., Patriarca F., Sorasio R., et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 91 (2006) 837-839
    • (2006) Haematologica , vol.91 , pp. 837-839
    • Bruno, B.1    Patriarca, F.2    Sorasio, R.3
  • 9
    • 33645737409 scopus 로고    scopus 로고
    • Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
    • van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 107 (2006) 3415-3416
    • (2006) Blood , vol.107 , pp. 3415-3416
    • van de Donk, N.W.1    Kroger, N.2    Hegenbart, U.3
  • 10
    • 0033803718 scopus 로고    scopus 로고
    • Neurotoxicity of calcineurin inhibitors: impact and clinical management
    • Bechstein W.O. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 13 (2000) 313-326
    • (2000) Transpl Int , vol.13 , pp. 313-326
    • Bechstein, W.O.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.